サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1786580

女性不妊診断の世界市場

Female Infertility Diagnosis

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
女性不妊診断の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

女性不妊診断の世界市場は2030年までに69億米ドルに達する見込み

2024年に47億米ドルと推定される女性不妊診断の世界市場は、2024～2030年の分析期間においてCAGR 6.7%で成長し、2030年には69億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである卵巣予備能検査は、CAGR 5.4％を記録し、分析期間終了時には26億米ドルに達すると予測されます。子宮卵管造影検査セグメントの成長率は、分析期間中CAGR 8.8％と推定されます。

米国市場は13億米ドルと推定、中国はCAGR10.3％で成長予測

米国の女性不妊診断市場は2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2024～2030年のCAGRは10.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4％と6.4％と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界の女性不妊診断市場-主要動向と促進要因のまとめ

女性不妊診断が現代ヘルスケアでかつてない注目を集める理由とは？

世界の不妊症の増加により、女性不妊診断は生殖医療イノベーションの最前線に位置しています。生殖年齢にあるカップルの推定8～12％が世界中で不妊症に悩まされており、女性は排卵障害、子宮内膜症、子宮の異常、卵巣予備能の低下などの根本的な原因を明らかにするために、ますます診断的評価を受けるようになっています。出産の遅れ、都市化、意識の向上などの社会規範の変化が、診断率を高める一因となっています。女性が高齢で妊娠を試みることが多くなったため、加齢に伴う不妊症やホルモンバランスの乱れが目立つようになり、包括的な診断戦略が必要となっています。現在の臨床ワークフローは、ホルモン値検査や経膣超音波検査などの基本的な評価から始まり、子宮卵管造影検査（HSG）、腹腔鏡検査、遺伝子スクリーニング、卵巣予備能評価などの先進的技術へと進んでいくのが一般的です。このような需要を後押ししているのが、特に都心部で、迅速な診断サービスを一カ所で提供する不妊治療専門クリニックの増加です。新興諸国では、ヘルスケアリテラシーの向上と政府の支援によるリプロダクティブヘルスプログラムが社会的スティグマを取り払い、より多くの女性がタイムリーな診断サポートを求めることを後押ししており、市場拡大にさらなる弾みをつけています。

診断技術は女性不妊検査の将来をどのように形成しているか？

より早く、より正確で、より低侵襲な評価を可能にする技術の進歩によって、女性不妊診断の状況は急速に変化しています。人工知能（AI）と機械学習は超音波画像診断とホルモン分析に応用され、診断精度とパターン認識を高めています。3Dや4Dの超音波画像診断のような技術革新は、子宮や卵巣の構造に関する優れた解剖学的洞察を提供し、先進的な腹腔鏡検査ツールは骨盤の異常をリアルタイムで高精細に可視化します。さらに、より高い感度と特異度を持つホルモン測定キットの開発により、エストロゲン、FSH、LH、AMH、プロラクチンレベルの異常の検出が容易になりました。遺伝学的検査もまた、特に反復流産や早発卵巣不全に関連する染色体や遺伝性疾患の特定において、ますます関連性を増してきています。AMH値や排卵追跡のための家庭用不妊検査キットの普及は、特に技術に精通しプライバシーを重視する消費者の間で、利用しやすさを高めています。これらの技術革新と並行して、統合されたデジタルプラットフォームと遠隔医療相談は、検査結果を統合し、専門医との遠隔相談を容易にし、女性の生殖プロファイルに基づいてパーソナライズされた診断経路を可能にすることによって、診断の旅を合理化しています。

どのような社会的・文化的力学が世界の診断需要を形成しているのか？

不妊や母性に対する社会的態度は、女性がいつ、どこで、どのように不妊診断を受けるかを決定する上で重要な役割を果たしています。多くの先進国では、生殖補助医療（ART）の正常化により、女性は将来の家族計画に向けた積極的なステップとして、より早期の診断検査を求めるようになっています。結婚が遅れ、教育、キャリア開発、経済的安定などの優先事項が変化していることが影響し、女性は20代後半から30代で、多くの場合、症状が出る前に不妊検査を受けるようになっています。これとは対照的に、伝統的社会では、不妊症は依然として高い汚名を着せられており、女性は妊娠しなければならないという大きな社会的プレッシャーに直面する可能性があります。このような文化的圧力に対抗するため、教育キャンペーン、不妊症啓発週間、NGO主導のアウトリーチプログラムなど、不妊症の道徳的性質ではなく医療的性質を強調するものが増えてきています。さらに、地域、所得、ヘルスケアインフラによるアクセス格差は、市場浸透に影響を与え続けています。低・中所得国では、都市と農村の格差が質の高い診断薬へのアクセスを左右することが多いが、移動クリニックや補助金付きの検査イニシアティブがこうした格差を埋め始めています。不妊擁護活動、有名人のオープンな発言、メディアキャンペーンなども、このテーマを主流にしつつあり、タブーを打ち破り、多様な層の診断需要に拍車をかけています。

地域や人口動態を問わず市場成長を促進する中核要因は何か？

女性不妊診断市場の成長は、医療技術の進化、患者層の変化、ヘルスケアシステムの優先順位に関連するいくつかの要因によって牽引されています。最も重要な促進要因のひとつは、初産時の母親の年齢が上昇していることであり、これは不妊合併症の可能性を本質的に高め、より早期かつ頻繁な診断評価を促しています。また、市場において不妊治療に特化した医療保険や保険償還施策が広く利用できるようになったことで、高コストの診断がより多くの人々にとって利用しやすくなっています。卵巣予備能を評価するためのAMH検査や生殖障害の遺伝子パネルの使用など、診断精度の進歩により、早期の妊孕性計画に診断が不可欠となっています。診断と治療を一括して提供する不妊治療センターの急増は、特に都市部やキャリア志向の女性の利便性と妊娠率を高めています。もう一つの重要な要因は、世界的にARTサイクルが急増していることで、最適な治療プロトコルを選択するためには正確な診断が不可欠です。政府や民間企業も不妊治療のインフラ拡充に投資しており、インド、中国、中東の一部などでは、早期スクリーニングと啓発を対象にした取り組みが行われています。最後に、積極的な健康行動をとる傾向が高いミレニアル世代とZ世代におけるホルモンとリプロダクティブヘルス意識の高まりが、市場基盤を拡大し、個別化されたデータ主導型の診断ソリューションに対する需要を生み出しています。

セグメント

検査（卵巣予備能検査、子宮卵管造影検査、ホルモン検査、その他の検査）

調査対象企業の例

  • Bayer AG
  • Carrot Fertility
  • CCRM Fertility
  • Dallas Fort Worth Fertility Associates
  • Extend Fertility
  • Ferring Pharmaceuticals
  • Hertility Health
  • Institute for Human Reproduction
  • Las Vegas Fertility
  • Main Line Fertility
  • Mankind Pharma
  • Merck KGaA
  • Novartis International AG
  • Overlake Reproductive Health
  • Pacific Fertility Center Los Angeles（PFCLA）
  • Pfizer Inc.
  • Proov
  • San Diego Fertility Center
  • Selectivity
  • Wisconsin Fertility Institute

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや産業固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）による企業の競合の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロとマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の展望

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30917

Global Female Infertility Diagnosis Market to Reach US$6.9 Billion by 2030

The global market for Female Infertility Diagnosis estimated at US$4.7 Billion in the year 2024, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Ovarian Reserve Testing, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Hysterosalpingography Test segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 10.3% CAGR

The Female Infertility Diagnosis market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Female Infertility Diagnosis Market - Key Trends & Drivers Summarized

Why Is Female Infertility Diagnosis Gaining Unprecedented Attention in Modern Healthcare?

The rising global prevalence of infertility is placing female infertility diagnosis at the forefront of reproductive healthcare innovation. With an estimated 8-12% of reproductive-aged couples affected by infertility worldwide, women increasingly undergo diagnostic evaluations to uncover underlying causes such as ovulatory disorders, endometriosis, uterine abnormalities, or diminished ovarian reserve. Changing societal norms-including delayed childbearing, urbanization, and increased awareness-have further contributed to higher diagnosis rates. As women now often attempt pregnancy at older ages, age-related infertility and hormonal imbalances have become more prominent, necessitating comprehensive diagnostic strategies. Clinical workflows now typically begin with basic evaluations such as hormone level testing and transvaginal ultrasounds, progressing to advanced techniques like hysterosalpingography (HSG), laparoscopy, genetic screening, and ovarian reserve assessments. This demand is bolstered by a growing number of specialized fertility clinics, particularly in urban centers, offering rapid diagnostic services under one roof. In developing countries, rising healthcare literacy and government-backed reproductive health programs are helping dismantle social stigmas and encouraging more women to seek timely diagnostic support, adding further momentum to the market’s expansion.

How Is Diagnostic Technology Shaping the Future of Female Fertility Assessments?

The landscape of female infertility diagnosis is being rapidly transformed by technological advancements that enable earlier, more accurate, and minimally invasive evaluations. Artificial intelligence (AI) and machine learning are being applied to ultrasound imaging and hormone analytics, enhancing diagnostic precision and pattern recognition. Innovations like 3D and 4D ultrasound imaging are providing superior anatomical insights into uterine and ovarian structures, while advanced laparoscopy tools are offering real-time, high-definition visualization of pelvic anomalies. Moreover, the development of hormone assay kits with higher sensitivity and specificity has made it easier to detect irregularities in estrogen, FSH, LH, AMH, and prolactin levels. Genetic testing is also becoming increasingly relevant, particularly in identifying chromosomal or hereditary conditions linked to recurrent miscarriages or premature ovarian failure. The proliferation of at-home fertility test kits for AMH levels or ovulation tracking is enhancing accessibility, particularly among tech-savvy and privacy-conscious consumers. Alongside these innovations, integrated digital platforms and telehealth consultations are streamlining the diagnostic journey by consolidating test results, facilitating remote consultations with specialists, and enabling personalized diagnostic pathways based on a woman’s reproductive profile.

What Social and Cultural Dynamics Are Shaping Diagnostic Demand Worldwide?

Social attitudes toward fertility and motherhood are playing a critical role in determining how, when, and where women seek infertility diagnoses. In many developed nations, the normalization of assisted reproductive technologies (ART) has prompted women to pursue earlier diagnostic testing as a proactive step toward future family planning. Delayed marriages and shifting priorities-such as education, career development, and financial stability-are influencing women to seek fertility assessments in their late twenties and thirties, often before symptoms arise. In contrast, in traditional societies, infertility remains highly stigmatized, and women may face immense societal pressure to conceive, pushing them to seek diagnosis quickly-often in secrecy or without adequate information. This cultural pressure is increasingly being countered by educational campaigns, fertility awareness weeks, and NGO-led outreach programs that emphasize the medical, not moral, nature of infertility. Additionally, access disparities-based on geography, income, and healthcare infrastructure-continue to influence market penetration. In low- and middle-income countries, urban-rural divides often determine access to quality diagnostics, though mobile clinics and subsidized testing initiatives are beginning to bridge these gaps. Fertility advocacy, celebrity openness, and media campaigns are also making the topic more mainstream, breaking taboos and fueling diagnostic demand across diverse demographics.

Which Core Factors Are Propelling Market Growth Across Regions and Demographics?

The growth in the Female Infertility Diagnosis market is driven by several factors tied to medical technology evolution, shifting patient demographics, and healthcare system priorities. One of the most significant drivers is the increasing maternal age at first childbirth, which inherently raises the likelihood of fertility complications and prompts earlier and more frequent diagnostic evaluations. The widespread availability of fertility-focused health insurance and reimbursement policies in developed markets is also making high-cost diagnostics more accessible to a larger population. Advances in diagnostic accuracy, including the use of AMH testing to assess ovarian reserve and genetic panels for reproductive disorders, are making diagnostics indispensable in early fertility planning. The proliferation of fertility centers offering bundled diagnostic and treatment services under one umbrella is enhancing convenience and uptake, particularly among urban and career-oriented women. Another critical factor is the surge in ART cycles globally, where precise diagnosis is essential for selecting optimal treatment protocols. Governments and private players are also investing in expanding fertility infrastructure, with initiatives in countries like India, China, and parts of the Middle East targeting early screening and awareness. Finally, growing awareness of hormonal and reproductive health among millennials and Gen Z, who are more likely to engage in proactive health behaviors, is expanding the market base and creating demand for personalized, data-driven diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Female Infertility Diagnosis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test (Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing, Other Tests)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Bayer AG
  • Carrot Fertility
  • CCRM Fertility
  • Dallas Fort Worth Fertility Associates
  • Extend Fertility
  • Ferring Pharmaceuticals
  • Hertility Health
  • Institute for Human Reproduction
  • Las Vegas Fertility
  • Main Line Fertility
  • Mankind Pharma
  • Merck KGaA
  • Novartis International AG
  • Overlake Reproductive Health
  • Pacific Fertility Center Los Angeles (PFCLA)
  • Pfizer Inc.
  • Proov
  • San Diego Fertility Center
  • Selectivity
  • Wisconsin Fertility Institute

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Female Infertility Diagnosis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Maternal Age Trends Throw the Spotlight on Early and Accurate Female Infertility Diagnosis
    • Delayed Family Planning Among Urban Women Spurs Demand for Comprehensive Fertility Assessments
    • Increased Awareness and Social Acceptance of Infertility Issues Strengthens the Business Case for Diagnostic Services
    • Advancements in Hormonal Biomarkers and Genetic Testing Expand Addressable Market for Precision Diagnostics
    • Growing Integration of AI and Machine Learning in Reproductive Health Drives Adoption of Predictive Diagnostic Tools
    • Access to Fertility Services in Emerging Economies Generates New Opportunities for Diagnostic Market Penetration
    • Surge in In Vitro Fertilization (IVF) Cycles Accelerates Demand for Pre-IVF Diagnostic Workups
    • Healthcare Policy Reforms and Insurance Coverage in Developed Markets Propel Growth of Diagnostic Procedures
    • Rise in Polycystic Ovary Syndrome (PCOS) and Endometriosis Incidence Fuels Demand for Early Diagnostic Interventions
    • Telehealth and At-Home Diagnostic Kits Drive Adoption of Convenient and Non-Invasive Fertility Testing Solutions
    • Clinical Focus on Personalized Reproductive Medicine Sustains Growth in Advanced Diagnostic Methodologies
    • Diagnostic Innovations in Ovarian Reserve and Tubal Patency Testing Broaden Scope for Early Detection
    • Psychological and Emotional Burdens of Infertility Create Opportunities for Integrated Diagnosis and Counseling Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Female Infertility Diagnosis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Female Infertility Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ovarian Reserve Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ovarian Reserve Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Ovarian Reserve Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hysterosalpingography Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Hysterosalpingography Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Hysterosalpingography Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hormone Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hormone Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hormone Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: Canada 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • JAPAN
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Japan 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • CHINA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: China 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • EUROPE
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Female Infertility Diagnosis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • FRANCE
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: France 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • GERMANY
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Germany 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Italy 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: UK 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Spain 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Russia 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of Europe 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Female Infertility Diagnosis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Australia 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • INDIA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: India 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: South Korea 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Female Infertility Diagnosis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Latin America 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Argentina 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Brazil 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Mexico 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Latin America 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Female Infertility Diagnosis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Middle East 15-Year Perspective for Female Infertility Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Iran 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Israel 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Saudi Arabia 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UAE 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Middle East 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030
  • AFRICA
    • Female Infertility Diagnosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Female Infertility Diagnosis by Test - Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Africa 15-Year Perspective for Female Infertility Diagnosis by Test - Percentage Breakdown of Value Sales for Ovarian Reserve Testing, Hysterosalpingography Test, Hormone Testing and Other Tests for the Years 2015, 2025 & 2030

IV. COMPETITION